PTK2 and cancer: These disparities may represent differences in the cancer models used, or may perhaps be explained by our observation that anti-OX40 alone only results in a relatively small upregulation of ICOS on CD8eff T-cells, while anti-OX40 in combination with a FAK inhibitor results in a much greater upregulation of ICOS expression.